Polycystic ovary syndrome risk factors: Difference between revisions
No edit summary |
Aditya Ganti (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Common risk factors in the development of Polycystic ovary syndrome are hyperinsulinemia secondary to insulin resistance, obesity, family history of PCOS among first-degree relatives, premature adrenarche, fetal androgen exposure, and low birth weight. | Common risk factors in the development of Polycystic ovary syndrome are [[hyperinsulinemia]] secondary to [[insulin resistance]], [[obesity]], family history of [[PCOS]] among first-degree relatives, [[Adrenarche|premature adrenarche]], fetal androgen exposure, and [[low birth weight]]. | ||
==Risk Factors== | ==Risk Factors== | ||
Common risk factors in the development of Polycystic ovary syndrome are: | Common risk factors in the development of Polycystic ovary syndrome are: | ||
*Hyperinsulinemia secondary to insulin resistance; associated with type 2 diabetes mellitus<ref name="pmid28642705">{{cite journal |vauthors=Sortino MA, Salomone S, Carruba MO, Drago F |title=Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols |journal=Front Pharmacol |volume=8 |issue= |pages=341 |year=2017 |pmid=28642705 |pmc=5463048 |doi=10.3389/fphar.2017.00341 |url=}}</ref> | *[[Hyperinsulinemia]] secondary to [[insulin resistance]]; associated with [[Diabetes mellitus type 2|type 2 diabetes mellitus]]<ref name="pmid28642705">{{cite journal |vauthors=Sortino MA, Salomone S, Carruba MO, Drago F |title=Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols |journal=Front Pharmacol |volume=8 |issue= |pages=341 |year=2017 |pmid=28642705 |pmc=5463048 |doi=10.3389/fphar.2017.00341 |url=}}</ref> | ||
*Obesity | *[[Obesity]] | ||
*Family history of PCOS among first-degree relatives | *Family history of PCOS among first-degree relatives | ||
*Premature adrenarche | *[[Adrenarche|Premature adrenarche]] | ||
*Fetal androgen exposure | *Fetal [[androgen]] exposure | ||
*Low birth weight | *[[Low birth weight]] | ||
==References== | ==References== | ||
Revision as of 15:04, 18 October 2017
|
Polycystic ovary syndrome Microchapters |
|
Differentiating Polycystic ovary syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polycystic ovary syndrome risk factors On the Web |
|
American Roentgen Ray Society Images of Polycystic ovary syndrome risk factors |
|
Risk calculators and risk factors for Polycystic ovary syndrome risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Common risk factors in the development of Polycystic ovary syndrome are hyperinsulinemia secondary to insulin resistance, obesity, family history of PCOS among first-degree relatives, premature adrenarche, fetal androgen exposure, and low birth weight.
Risk Factors
Common risk factors in the development of Polycystic ovary syndrome are:
- Hyperinsulinemia secondary to insulin resistance; associated with type 2 diabetes mellitus[1]
- Obesity
- Family history of PCOS among first-degree relatives
- Premature adrenarche
- Fetal androgen exposure
- Low birth weight
References
- ↑ Sortino MA, Salomone S, Carruba MO, Drago F (2017). "Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols". Front Pharmacol. 8: 341. doi:10.3389/fphar.2017.00341. PMC 5463048. PMID 28642705.